OPKO Health Closes Acquisition of Two Phase 3 Products
Posted on March 04, 2013 at 16:28 PM EST
OPKO Health, Inc. (NYSE: OPK ) announced that it has completed the acquisition of Cytochroma Inc. (Markham, Canada). Cytochroma's lead products include CTAP101 Capsules, a vitamin D prohormone to treat secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency, and Fermagate Tablets, a new